Season’s Greetings

Dear Readers, On behalf of everyone at biotuesdays.com, I would like to wish you all a Joyous Christmas and a Happy New Year.  We are taking a short break to spend time with family and friends this holiday season.  But, we will be back in full swing with our next Tuesday Feature on January 4, [...]

YM reshuffles the Cytopia deck

YM BioSciences (AMEX:YMI; TSX:YM) got more than it bargained for with its recent acquisition of Australia’s Cytopia. “When we were buying the company, our sole interest was in CYT997, Cytopia’s lead vascular disrupting agent (VDA),” CEO David Allan told biotuesdays.com in an exclusive interview.  VDAs, which can disrupt the blood flow that feed tumours, became [...]

BioFinance 2010, Toronto, April 6-8: biotuesdays.com Will Be There

BioFinance is a leading investor conference in Canada for the life sciences industry.  This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector.  Presenting companies will span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, [...]

biotuesdays.com’s feature piece on Labopharm “in the news”

At approximately 8:00 AM ET today, this week’s feature article was posted to biotuesdays.com.  Written by Len Zehr, the piece provided Labopharm’s (TSX:DDS; NASDAQ:DDSS) CEO, James Howard-Tripp, with an opportunity to map out where his company is heading in 2010 and beyond.   In the first five hours alone, the post attracted more than 654 [...]